跳至主要内容
临床试验/NCT05537779
NCT05537779尚未招募不适用

Safety and Performance of Optivantage Multi-use Solution When Injecting Contrast Media to Subjects Requiring Contrast Enhanced CT Examination

Guerbet0 个研究点目标入组 100 人开始时间: 2022年10月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
Guerbet
入组人数
100
主要终点
Safety of Optivantage

研究概览

简要总结

The study is a prospective, single-arm observational multicenter clinical investigation.

The primary objective is to confirm the safety and performance of the Optivantage® Injection System when injecting contrast media to subjects requiring contrast-enhanced CT imaging, in multi-patient use.

详细描述

Each subject will undergo CT examination in multi-use context using Optivantage Dual-head Contrast Delivery System.

100 subjects are expected to be enrolled. The safety and performance of the injector will be evaluated.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
2 Years 至 100 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject referred for a contrast-enhanced CT examination using a power injector
  • Subject or legal representative for children, having provided written informed consent

排除标准

  • Subject weighting less than 10 kg
  • Pregnant or breastfeading woman subject
  • Subject with known allergy or hypersensitivity to contrast media
  • Subject has contra-indication(s) to CT scanner and/or contrast medium as per the Summary of Product Characteristics
  • Subject with peripherally inserted central catheter, central venous line, or port-A-catheter inserted for injection
  • Subject unlikely to comply with the CIP, e.g. uncooperative attitude and unlikelihood of completing the study

结局指标

主要结局

Safety of Optivantage

时间窗: Per procedure

Rate of extravasation

Performance of Optivantage

时间窗: Per procedure

Success of injection

次要结局

  • Device deficiencies(Per procedure)
  • Safety of Optivantage(Per procedure)

研究者

发起方
Guerbet
申办方类型
Industry
责任方
Sponsor

相似试验